Clinical Evaluation of Deferasirox For Removal of Cr+6 Ions In Rats
Journal Title: International Journal of Clinical Pharmacology & Toxicology(IJCPT) - Year 2013, Vol 2, Issue 7
Abstract
The present research aimed to characterize the potential efficiency of deferasirox in removing chromium after its administration for 60 days following two doses of 15 and 30 mg/kg Cr+6 to the body weight of the male Wistar rats every day. After chromium administration some abnormal clinical signs such as red staining around the eyes, greenish mottling on the liver, weakness and loss of hair and weight, were observed in rats. Deferasirox was given orally to different groups of rats for a period of one week immediately after chromium administration. After chelation therapy, animals were anesthetized with ether vapors and then chromium and iron concentrations in various tissues were determined by graphite furnace and flame atomic absorption spectrometry methods, respectively. The chelation therapy results showed that deferasirox was able to remove chromium ions from the body and at the same, iron levels in tissues and clinical symptoms were also reduced.
Authors and Affiliations
Marzieh Iranmanesh
Keywords
Related Articles
- EP ID EP201628
- DOI 10.19070/2167-910X-1300018
- Views 73
- Downloads 0
Gender based Dosing of Metoprolol in the Elderly using Population Pharmacokinetic Modeling and Simulations
Introduction: This article seeks to clarify if gender-based differences occur in the pharmacokinetics of metoprolol in the elderly patients. There are a series of physiologic changes that occur in the elderly ranging fro...
VKORC1 (-1639) Polymorphisms do not Affect Long-Term Stability of Anticoagulation with Warfarin
The extent of INR fall following vitamin K supplementation to patients on warfarin is related to VKORC1-1639G>A genotype, with those carrying the GG genotype demonstrating a significantly larger fall in INR compared to t...
Steady State Plasma Levels of Bupropion After Administration of 3x150 Mg Extended Release Reference Tablets and Switching to 1x450 Mg Extended Release 450ER Tablets
In order to provide patients who take 450 mg/day bupropion hydrochloride for the treatment of severe depressive disorder with a safe and convenient alternative to currently existing dose regimens, a high-dose bupropion E...
A Possible Association of Sex Hormone-Binding Globulin with Weight Gain in the Valproic Acid-Treated Female Patients with Epilepsy
Weight gain is a common adverse consequence of treatment with valproic acid. Although a low sex hormone-binding globulin (SHBG) level was shown to be an independent risk factor for the development of metabolic syndrome a...
Simulated Evaluation of Drug-Impaired Psychomotor Performance
The purpose of this placebo-controlled, randomized-crossover study was to evaluate a computer-based divided-attention task as a method for measure impaired human psychomotor performance. The ability of the divided-attent...